Fig 2. Illumina sequence analyses demonstrate enrichment of the protected 12 kb lambda DNA region.
Plots of aligned Illumina reads of the protection experiment mapped to the lambda target genome using BWA 0.7.12-r1039. Sample 1 had no Cas9/sgRNA and no exonuclease treatment with a 120,000:1 copy ratio of lambda to human DNA. Sample 2 had no Cas9/sgRNA and no exonuclease treatment with a 3,000:1 copy ratio of lambda to human DNA. Sample 3 had Cas9/sgRNA Lambda F2 and Lambda R6 treatment with exonucleases III and VII with a 120,000:1 lambda DNA to human genomic DNA copy ratio. Sample 4 had Cas9/sgRNA Lambda F2 and Lambda R6 treatment with exonucleases III and VII with a 3000:1 lambda DNA to human genomic DNA copy ratio.